Proteocyte AI

# Consider STRATICYTE™ and revolutionize the management of your Oral Pre-cancer (OPMD) patients.

WHAT'S YOUR PATIENT'S ORAL CANCER <u>RISK</u> SCORE?

Proteocyte AI
Straticyte® RISK REPORT
Certificate #6423.01

Sample, Patient
DOB: **15-Dec-1980**   Report Number: **STR22-1111-999**   Report Date: **15-Dec-2022**
Specimen Source/ID: **Oral mucosa* / 22-000001**   Biopsy Date: **5-Dec-2022**
Ordering Physician: **Dr. Requestor**

Predicted Risk Group   5-Year Progression Probability

Elevated Risk   **58%**
                                    95% CI (47%, 69%)

...cted Probability
Confidence Interval Upper Bound
Confidence Interval Lower Bound

Proteocyte AI
Straticyte® RISK REPORT
Certificate #6423.01

Sample, Patient
DOB: **15-Dec-1980**   Report Number: **STR22-1111-999**   Report Date: **15-Dec-2022**
Specimen Source/ID: **Oral mucosa* / 22-000001**   Biopsy Date: **5-Dec-2022**
Ordering Physician: **Dr. Requestor**

Predicted Risk Group   5-Year Progression Probability

Low Risk   **24%**
                                    95% CI (47%, 69%)

Straticyte reference ranges for cancer risk:
Elevated: >=28%; Low: <28%

Cumulative Progression Probability

Cancer Progression Probability (%)

Year

— Predicted Probability
— 95% Confidence Interval Upper Bound
— 95% Confidence Interval Lower Bound

The **STRATICYTE™** Test is available to order **NOW** in the US and Canada.

Order the test, **Proteocyte** does the rest.

STRATICYTE
Predicting the Risk of Developing Oral Cancer

Supported by:

AAOM
The American Academy of Oral Medicine

SPOHNC
SUPPORT FOR PEOPLE WITH ORAL AND HEAD AND NECK CANCER | EST. 1991

PROPATH

CENTER FOR ORAL PATHOLOGY™
DALLAS

MANAGING OPMD PATIENTS CAN BE A CHALLENGE.

Your patient has unfortunately been diagnosed with OPMD (Oral Potentially Malignant Disorder) and perhaps Dysplasia. Dysplasia grading is highly subjective with poor reproducibility and has limited prognostic value offering very confusing guidance.

> In a large retrospective study by Chaturvedi et al, of the leukoplakia patients that progressed to cancer 39.6% had no Dysplasia whatsoever.[1]

PROTEOCYTE AI can help with OPMD management by performing the prognostic STRATICYTE test using your patient's original biopsied tissue.

The **STRATICYTE™** test can be considered for all clinically significant **red and white patches** affecting oral mucosa.

Managing the Elevated-risk Patient.

Using AI-driven digital histopathology, S100A7 (a cancer promoting protein) along with cellular features from **your patient's original biopsy sample** are quantitatively measured.

Your patient's test results are compared with a large cohort of similar cases with many years of follow up. An **accurate, objective and individualized 5-year cancer risk score** is generated to support management of your OPMD patient.
(STRATICYTE™ test sensitivity 96%/NPV 96%) [2]

"Early detection is the key to saving lives and improving outcomes related to oral cancer. Straticyte™ is an innovative new test that can help us to better risk stratify patients and personalize their treatment."

Dr. Deepak Kademani, DMD, MD, FACS
Fellowship Director, Head and Neck
Oncologic and Reconstructive Surgery,
Minnesota Oral and Facial Surgery.

"Due to the uncertain progression of pre-cancerous lesions, STRATICYTE provides a quantified tool for predicting the transformation of a lesion to a life-threatening cancer.

All in all, STRATICYTE has been an invaluable tool in providing my patients with the best care possible. I am confident that STRATICYTE will be a powerful tool in the management of precancerous leukoplakia."

Dr James C. Melville, DDS FACS
Associate Professor
Department of Oral & Maxillofacial Surgery
Oral, Head & Neck Oncology and Microvascular
Reconstructive Surgery
University of Texas Health Science Center at Houston

ORDER THE STRATICYTE™ TEST ON-LINE!

Visit **proteocyte.com** or call: **1-833-5-PROTEO**
(1-833-577-6836)
email **proteocyte@patientcaresolutions.com**
and we will assist you.

Stay informed of future developments, relevant information, and complimentary webinars.

Scan this QR code or visit **caretoknowpro.com** to enroll with "Care to know", North America's leading source of webinars, industry information and peer insights.

The STRATICYTE™ test is a proprietary prognostic test offered by **Proteocyte AI**.

Proteocyte AI is a privately held corporation located in the MaRS Centre on Hospital Row in Toronto Canada.

STRATICYTE
Predicting the Risk of
Developing Oral Cancer

Proteocyte AI
MaRS Centre South Tower
101 College St. Suite 200
Toronto, Canada
M5G 1L7

1. Chaturvedi et al, "Oral leukoplakia and risk of progression to cancer: A population-based cohort study." *J Nat Can Inst.* (112) 1047, 2020 2. Proteocyte internal multi cohort study data, n = 302